Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells (Q39911338)

15 September 2017

title

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells (English)

1 reference

15 September 2017

main subject

chronic myeloid leukemia

0 references

bosutinib

1 reference

ChEBI release 2020-05-28

1 reference

12

1 reference

15 September 2017

O Hantschel

4

0 references

author name string

L L Remsing Rix

1

1 reference

15 September 2017

U Rix

2

1 reference

15 September 2017

J Colinge

3

1 reference

15 September 2017

K L Bennett

5

1 reference

15 September 2017

T Stranzl

6

1 reference

15 September 2017

A Müller

7

1 reference

15 September 2017

C Baumgartner

8

1 reference

15 September 2017

P Valent

9

1 reference

15 September 2017

M Augustin

10

1 reference

15 September 2017

J H Till

11

1 reference

15 September 2017

publication date

27 November 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

23

1 reference

15 September 2017

issue

3

1 reference

15 September 2017

page(s)

477-485

1 reference

Current and emerging treatment options in chronic myeloid leukemia

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Flying under the radar: the new wave of BCR-ABL inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

AXL is a potential target for therapeutic intervention in breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Biosignaling of mammalian Ste20-related kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

The GCK II and III subfamilies of the STE20 group kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

The dark side of the NGF family: neurotrophins in neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Cytogenetics of the chronic myeloid leukemia-derived cell line K562: karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

The tyrosine kinase FES is an essential effector of KITD816V proliferation signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Circumventing Resistance to Kinase-Inhibitor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

Imatinib as a paradigm of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.334

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2008.334

1 reference

Dimensions Publication ID

15 September 2017

1043735889

0 references

1 reference